Experienced in Marginal Zone Lymphoma (MZL)

Dr. Leon Bernal-Mizrachi

Hematology Oncology
Medical Ctr Blvd, 
Winston Salem, NC 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Experienced in Marginal Zone Lymphoma (MZL)
Medical Ctr Blvd, 
Winston Salem, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Leon Bernal-Mizrachi is a Hematologist Oncology provider in Winston Salem, North Carolina. Dr. Bernal-Mizrachi is rated as an Experienced provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). His top areas of expertise are Multiple Myeloma, B-Cell Lymphoma, Smoldering Multiple Myeloma, Non-Hodgkin Lymphoma, and Bone Marrow Aspiration. Dr. Bernal-Mizrachi is currently accepting new patients.

His clinical research consists of co-authoring 41 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Licenses
Internal Medicine in NC
Hospital Affiliations
Grady Memorial Hospital
Languages Spoken
English
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

Medical Ctr Blvd, Winston Salem, NC 27157

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 1 Study of Lenalidomide in Combination With EPOCH Chemotherapy for HTLV-Associated Adult T-Cell Leukemia-Lymphoma (ATLL)
A Phase 1 Study of Lenalidomide in Combination With EPOCH Chemotherapy for HTLV-Associated Adult T-Cell Leukemia-Lymphoma (ATLL)
Enrollment Status: Recruiting
Publish Date: October 20, 2025
Intervention Type: Drug, Procedure
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Lenalidomide, Prednisone, Vincristine Sulfate
Study Phase: Phase 1
An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) in Patients With Multiple Myeloma Previously Receiving a Bortezomib-Based Induction Regimen (US MM-6)
An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) in Patients With Multiple Myeloma Previously Receiving a Bortezomib-Based Induction Regimen (US MM-6)
Enrollment Status: Active_not_recruiting
Publish Date: March 28, 2025
Intervention Type: Drug
Study Drugs: Ixazomib, Lenalidomide, Dexamethasone
Study Phase: Phase 4
View 1 Less Clinical Trial

41 Total Publications

Corrigendum to "The SMAC mimetic RMT5265.2HCL induces apoptosis in EBV and HTLV-I associated lymphoma cells by inhibiting XIAP and promoting the mitochondrial release of cytochrome C and SMAC" [Leuk. Res., 36(2011) 784-90].
Corrigendum to "The SMAC mimetic RMT5265.2HCL induces apoptosis in EBV and HTLV-I associated lymphoma cells by inhibiting XIAP and promoting the mitochondrial release of cytochrome C and SMAC" [Leuk. Res., 36(2011) 784-90].
Journal: Leukemia research
Published: October 11, 2025
Similar Doctors
Advanced in Marginal Zone Lymphoma (MZL)
Dr. Heidi D. Klepin
Hematology Oncology | Oncology | Hematology
Advanced in Marginal Zone Lymphoma (MZL)
Dr. Heidi D. Klepin
Hematology Oncology | Oncology | Hematology

Wake Forest University Health Sciences

Medical Ctr Blvd, 
Winston Salem, NC 
 (0.1 miles away)
336-716-2734
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Heidi Klepin is a Hematologist Oncology specialist and an Oncologist in Winston Salem, North Carolina. Dr. Klepin is rated as a Distinguished provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). Her top areas of expertise are Acute Myeloid Leukemia (AML), Breast Cancer, Leukemia, and Angiosarcoma. Dr. Klepin is currently accepting new patients.

Advanced in Marginal Zone Lymphoma (MZL)
Dr. Richard A. Krumdieck
Hematology Oncology
Advanced in Marginal Zone Lymphoma (MZL)
Dr. Richard A. Krumdieck
Hematology Oncology
170 Medical Park Road, Ste 101, 
Mooresville, NC 
 (49.4 miles away)
704-799-3946
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Richard Krumdieck is a Hematologist Oncology provider in Mooresville, North Carolina. Dr. Krumdieck is rated as a Distinguished provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). His top areas of expertise are Carcinoid Syndrome, Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET), Paget Disease of the Breast, and Myelodysplastic Syndrome (MDS). Dr. Krumdieck is currently accepting new patients.

Experienced in Marginal Zone Lymphoma (MZL)
Dr. Rakhee R. Vaidya
Hematology Oncology | Hematology | Oncology
Experienced in Marginal Zone Lymphoma (MZL)
Dr. Rakhee R. Vaidya
Hematology Oncology | Hematology | Oncology

Wake Forest University Health Sciences

Medical Ctr Blvd, 
Winston Salem, NC 
 (0.1 miles away)
336-716-2734
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Rakhee Vaidya is a Hematologist Oncology specialist and a Hematologist in Winston Salem, North Carolina. Dr. Vaidya is rated as a Distinguished provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). Her top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Vaidya is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bernal-Mizrachi's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 44 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile